Search clinical trials for: GS-9451 tablet

Total 7915 results

Gilead Sciences

Completed

Evaluation of the Safety, Tolerability, Pharmacokinetics, and Activity of GS-9450 in Subjects With Chronic HCV

HCV Infection

United States, Netherlands, Germany
Gilead Sciences

Completed

Safety, Tolerability, Pharmacokinetics and Activity of GS-9450 in Adults With Non-Alcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis

United States, France
Gilead Sciences

Completed

GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus

Hepatitis C, Chronic

United States, Puerto Rico, Australia
Gilead Sciences

Completed

GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection

Hepatitis C, Chronic

United States, Puerto Rico
Gilead Sciences

Completed

Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection

Hepatitis C, Chronic

United States, Puerto Rico
Gilead Sciences

Completed

GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection

Chronic Genotype 1a or 1b HCV Infection

United States, Canada, Puerto Rico
Tasly Pharmaceutical Group Co., Ltd

Completed

Study of Jitongning Tablet to Treat Spondyloarthritis

Spondyloarthritis

China
National Institute of Allergy and Infectious Diseases...

Completed

Combination Therapy for Chronic Hepatitis C Infection

Hepatitis C, Chronic

United States
Gilead Sciences

Terminated

GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype

Chronic Hepatitis C

United States, Australia, Canada, New Zealand
Gilead Sciences

Terminated

Efficacy and Safety Study of GS-9450 Treatment for 6 Months in Patients With Chronic Hepatitis C Virus Infection

HCV Infection

United States, United Kingdom, Germany, Canada, Puerto Rico, Poland
Gilead Sciences

Completed

A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

Hepatitis C, Chronic

United States, United Kingdom, France, Germany, Netherlands, Belgium, Austria, Poland
Gilead Sciences

Completed

A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection

Hepatitis C, Chronic

United States, Puerto Rico
Gilead Sciences

Completed

Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection and Cirrhosis

Hepatitis C Virus Infection

United States
Gilead Sciences

Withdrawn

A Phase 1 Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS 9411 in Subjects With Cystic Fibrosis (CF)

Cystic Fibrosis | Mucociliary Clearance

Australia
Gilead Sciences

Completed

A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Trial of GS-9411 in Healthy Volunteers

Cystic Fibrosis | Mucociliary Clearance | Airway Hydration

Australia
Gilead Sciences

Completed

Trial to Assess the Safety, Tolerability and Pharmacokinetics of GS-9411 in Healthy Male Volunteers

Cystic Fibrosis

Australia
Gilead Sciences

Completed

A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS-9411 in Healthy Male Volunteers

Cystic Fibrosis | Mucociliary Clearance | Airway Hydration

Australia
Akros Pharma Inc.

Completed

Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis (IMPACT-PS)

Skin Diseases | Psoriasis | Plaque Psoriasis

United States, Canada, Poland
Gilead Sciences

Completed

GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection

Hepatitis C, Chronic

United States, Germany
Gilead Sciences

Active, not recruiting

A Study of GS-5423 and GS-2872 in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection

HIV Infections

United States, Australia, Puerto Rico, Canada
Yiling Pharmaceutical Inc.

Completed

A Single-dose Study to Investigate the Tolerance and Pharmacokinetics of Finamine Tablets in China

Parkinson Disease

China
The National Institutes of Pharmaceutical R&D Co...

Completed

A Safety, Tolerability, and Pharmacokinetic Study of NIP292 in Healthy Normal Subjects

Idiopathic Pulmonary Fibrosis

United States
Sunshine Lake Pharma Co., Ltd.

Completed

The Tolerability , Pharmacokinetics and Pharmacodynamics Study of HEC96719 Tablets in Healthy Adult Subjects

Nonalcoholic Steatohepatitis (NASH)

China
Gilead Sciences

Recruiting

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1)

HIV-1-infection

Japan, Germany, France, United States, Spain, Korea, Republic of, South Africa, Australia, Argentina, Canada, Dominican Republic, Italy, Puerto Rico, Taiwan, United Kingdom
Atridia Pty Ltd.

Completed

A Trial of HRS-7085 Tablet in Healthy Participants With and Without Food Effect.

Inflammatory Bowel Disease

Australia
Lexicon Pharmaceuticals

Completed

A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome

Irritable Bowel Syndrome

United States
Harmony Biosciences, LLC

Active, not recruiting

A Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension

Prader-Willi Syndrome

United States
Gilead Sciences

Active, not recruiting

Study of HBV Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B

Chronic Hepatitis B

Taiwan, New Zealand
Paratek Pharmaceuticals Inc

Active, not recruiting

Oral Omadacycline vs. Placebo in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc)

Mycobacterium Infections, Nontuberculous | Nontuberculous Mycobacterial Lung Disease | Mycobacterium Abscessus Infection | Nontuberculous Mycobacterial Pulmonary Infection

United States
Dong Wha Pharmaceutical Co. Ltd.

Completed

The Phase I Clinical Study to Evaluate the Pharmacokinetics of Dw1029M in Healthy Male Volunteer

Diabetic Kidney Disease

Korea, Republic of
Rigshospitalet, Denmark

Completed

The Association Between Hyponatremia and Osteoporosis in Patients With Epilepsy.

Hyponatremia | Metabolic Bone Disease

Denmark
Gilead Sciences

Completed

Safety and Effectiveness Study of an Experimental Topical Ointment (GS-9191) for the Treatment of Genital Warts

Genital Warts

United States
Gilead Sciences
Ono Pharmaceutical Co. Ltd; Galapagos NV

Completed

Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome

Sjogren's Syndrome

United States, Spain, United Kingdom, Poland
Northwestern University
National Institute on Aging (NIA)

Recruiting

Tau PET Imaging in Atypical Dementias

Primary Progressive Aphasia With Suspected Alzheimer's Disease

United States
Sinew Pharma Inc.

Completed

Phase I Pharmacokinetic Study of HUYPS-1 in Healthy Volunteers

Nonalcoholic Steatohepatitis

Taiwan
Gilead Sciences

Completed

Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor (POLARIS-4)

Hepatitis C Virus Infection

United States, France, United Kingdom, Germany, Canada, Australia, New Zealand, Puerto Rico
Gilead Sciences

Completed

Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis (POLARIS-3)

Hepatitis C Virus Infection

United States, France, United Kingdom, Germany, Australia, Canada, New Zealand, Puerto Rico
Aveiro University

Completed

Table to Tablet (T2T): A Novel Intervention Framework for Children With Speech Sound Disorders

Speech Disorders

Portugal
Columbia University
National Institute of Neurological Disorders and Stroke (NINDS)

Completed

Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations

Tauopathies | Frontotemporal Dementia (FTD) | Frontotemporal Lobar Degeneration (FTLD)

United States
Gesynta Pharma AB
CTC Clinical Trial Consultants AB; RISE Research Institutes of Sweden AB

Completed

A Study in Healthy Subjects to Evaluate Pharmacokinetics and Food Effect After Dosing of GS-248

Pharmacokinetic

Sweden
Gilead Sciences

Completed

Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV Infection

Chronic Hepatitis C

New Zealand
Gilead Sciences

Terminated

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GS-3583 in Participants With Advanced Solid Tumors

Advanced Solid Tumors

United States
Gilead Sciences

Completed

A Phase 1 Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of GS-5806

RSV Infection

United States
Fulcrum Therapeutics

Completed

Relative Bioavailability and Food Effect Study of Losmapimod 15 mg Tablets

Healthy Adult Subjects

United States
Gilead Sciences

Completed

Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy (POLARIS-2)

Hepatitis C

United States, France, United Kingdom, Germany, Canada, Australia, New Zealand, Puerto Rico
Gilead Sciences

Completed

Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection (LEPTON)

Chronic Hepatitis C

New Zealand
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of Teropavimab and Zinlirvimab in Combination With Lenacapavir (GS-6207) in Virologically Suppressed Adults With HIV-1 Infection

HIV-1 Infection

United States
Otsuka Pharmaceutical Co., Ltd.

Completed

A Clinical Pharmacology Trial of Brexpiprazole Once-weekly (QW) Formulation Administered as Single and Multiple Oral Doses

Schizophrenia

Japan
Gilead Sciences
Galapagos NV

Completed

Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)

Cutaneous Lupus Erythematosus

United States, Canada
Aelix Therapeutics
Gilead Sciences

Completed

Safety, Tolerability and Immunogenicity of MVA.HTI and ChAdOx1.HTI With Vesatolimod in HIV-1 Positive Patients (AELIX-003)

HIV/AIDS

Spain

3

Subscribe